Observational Study of Ultravist in Patients Requiring CECT

The Image Quality and Radiation Dose of CECT With Ultravist® in Patients With Abdominal Pelvic Disease - INDEX

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01415414

Acronym

INDEX

Enrollment

11660

Registered

2011-08-12

Start date

2011-09-30

Completion date

2013-11-30

Last updated

2015-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diagnostic Imaging

Keywords

Image quality, CNR, SNR, Abdominal, Pelvic

Brief summary

It is a prospective, non-interventional, multi-center study. The primary objective of this study is to evaluate the image quality of Ultravist in patients requiring contrast-enhanced CT considering the routine use in patient population's, region's indication.

Interventions

DRUGIopromide (Ultravist, BAY86-4877)

CT enhancement for abdominal or pelvic scan. Generally doses of up to 1.5 g iodine per kg body weight are well tolerated

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients undergoing contrast enhanced CT Imaging with Ultravist (iopromide) in abdomen or pelvis.

Exclusion criteria

* There is no other

Design outcomes

Primary

Measure	Time frame
Image quality evaluated by calculated CNR (Contrast to Noise Ratio)	1 day

Secondary

Measure	Time frame
Image quality evaluated by calculated SNR (Signal Noise Ratio)	1 day
Descriptive analysis of contrast medial injection protocol	1 day
Radiation dose (CTDIvol)	1 day

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026